Skip to Content

Acuvail FDA Approval History

FDA Approved: Yes (First approved July 22, 2009)
Brand name: Acuvail
Generic name: ketorolac tromethamine
Dosage form: Ophthalmic Solution
Company: Allergan, Inc.
Treatment for: Postoperative Ocular Inflammation

Acuvail (ketorolac tromethamine) is a preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation following cataract surgery.

Development Timeline for Acuvail

DateArticle
Jul 23, 2009ApprovalAllergan Receives FDA Approval for Acuvail Ophthalmic Solution for the Treatment of Pain and Inflammation Following Cataract Surgery

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.